Abiraterone in Metastatic Prostate Cancer

Sdílet
Vložit
  • čas přidán 13. 12. 2015
  • The panelists, Raoul S. Concepcion, MD, FACS; Michael Fabrizio, MD, FACS; Jorge A. Garcia, MD, FACP; Charles J. Ryan, MD; and Judd W. Moul, MD, FACS, elaborate on the use of abiraterone, an androgen synthesis inhibitor, in metastatic prostate cancer.

Komentáře • 2